A Published-Ahead-of-Print version of this article was made available online at http://link.springer.com/article/10. 1007/s40261-013-0151-4 on 09 November 2013. Errors were subsequently identified in that version of the article, and the following corrections should be noted: Section 3.1, line 5, which previously read: ''As shown in Table 2 , among US patients, 29 (56.9 %) in the paricalcitol group and 16 (34.0 %) in the cinacalcet group reached this endpoint (a difference of 23 %, p = 0.0235).'' Should read:
''As shown in Table 3 , among US patients, 29 (56.9 %) in the paricalcitol group and 16 (34.0 %) in the cinacalcet group reached this endpoint (a difference of 23 %, p = 0.0235).'' Section 3.3, first paragraph, line 8, which previously read: ''Table 3 also shows the difference between the paricalcitol and cinacalcet groups in the proportions of patients who responded, based on each endpoint included (based on data in Table 2 ).'' Should read:
''Table 4 also shows the difference between the paricalcitol and cinacalcet groups in the proportions of patients who responded, based on each endpoint included (based on data in Table 3 ).'' Section 3.3, third paragraph, line 1, which previously read: '' Figure 1 is a scatterplot of all 1,000 bootstrap replicates, with the x-axis representing the incremental cost and the y-axis representing the incremental effectiveness of the paricalcitol-based regimen compared with the cinacalcetbased regimen, where effectiveness is the proportion of subjects reaching an iPTH level of 150-300 pg/mL.'' Should read: Figure 1 is a scatterplot of all 1,000 bootstrap replicates, with the x-axis representing the incremental effectiveness and the y-axis representing the incremental cost of the paricalcitol-based regimen compared with the cinacalcetbased regimen, where effectiveness is the proportion of subjects reaching an iPTH level of 150-300 pg/mL.''
